Product
Substance P
2 clinical trials
2 indications
Indication
Skin DiseasesIndication
HypertensionClinical trial
An Open Label, Single Centre, Enabling Study to Investigate the Optimum Method for Use of Intradermal Substance P as a Challenge Agent in Healthy ParticipantsStatus: Completed, Estimated PCD: 2021-07-21
Clinical trial
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1Status: Active (not recruiting), Estimated PCD: 2025-07-01